Compare Lucid Group Inc (LCID) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Pfizer Inc — how do they compare? Lucid Group Inc trades at $3.81 (market cap $1.51B), while Pfizer Inc trades at $28.24 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 105× Lucid Group Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Pfizer Inc for 158 Days on average.
| LCID | PFE | |
|---|---|---|
Market Cap | $1.51B | $158.56B |
Volume | 12,333,745 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.92 | $29.02 |
52-Week Low | $3.82 | $23.67 |
Typical Hold Time | 45 Days | 158 Days |
Enterprise Value | $4.40B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.79, down 2.57% on the day, reflecting ongoing investor concerns about the company's financial performance. The stock shows bearish technical signals with negative moving averages and faces fundamental challenges including significant losses, negative profit margins, and cash burn. Recent news highlights management's focus on cost savings and strategic partnerships while delaying key product launches like the Cosmos SUV.
The outlook remains challenging with persistent losses and high cash burn requiring additional financing. Analyst consensus is cautious with only 13% buy ratings and a $7.60 price target representing potential upside. Key risks include execution delays, competitive pressure, and potential dilution from future capital raises.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
